1-3 of 3
John Lunec
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Dual Targeting of MDM2 and BCL2/Bclxl Demonstrates Potent Synergistic Activity in High-Risk Adult Acute Lymphoblastic Leukemia

Hayden L Bell, Mankaran Singh, Helen J Blair, Olaf Heidenreich, Frederik W. van Delft, Anthony V. Moorman, John Lunec, Julie Irving
Journal: Blood
Blood (2022) 140 (Supplement 1): 9181–9182.
https://doi.org/10.1182/blood-2022-159573
Published: 2022
Journal Articles

Preclinical Investigation of the p53-MDM2 Antagonist Idasanutlin (RG7388) Demonstrates Significant Activity in High Risk Adult Acute Lymphoblastic Leukemia

Hayden L Bell, Mankaran Singh, MSc, Helen J Blair, PhD, Frederik W. van Delft, MD PhD, Anthony V. Moorman, PhD, John Lunec, PhDMRCR(Hon) FRCPath, Julie Irving, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38.
https://doi.org/10.1182/blood-2020-139536
Published: 2020
Journal Articles

The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia

Carmela Ciardullo, PhD, Laura Woodhouse, PhD, Erhan Aptullahoglu, MSc, Jonathan P Wallis, MD, Helen J Marr, MD PhD, Scott R Marshall, MD, Nick Bown, PhD, Elaine Willmore, PhD, John Lunec, PhD
Journal: Blood
Blood (2016) 128 (22): 893.
https://doi.org/10.1182/blood.V128.22.893.893
Published: 2016